These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33037767)

  • 1. Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports.
    Schifano N; Chiappini S; Castiglione F; Salonia A; Schifano F
    Low Urin Tract Symptoms; 2021 Apr; 13(2):230-237. PubMed ID: 33037767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems.
    Schifano F; Chiappini S; Corkery JM; Guirguis A
    Front Pharmacol; 2019; 10():46. PubMed ID: 30774595
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
    Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
    J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
    McLernon DJ; Bond CM; Hannaford PC; Watson MC; Lee AJ; Hazell L; Avery A;
    Drug Saf; 2010 Sep; 33(9):775-88. PubMed ID: 20701410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
    O' Donovan B; Rodgers RM; Cox AR; Krska J
    Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.
    Schifano F; Chiappini S; Corkery JM; Guirguis A
    Int J Neuropsychopharmacol; 2019 Apr; 22(4):270-277. PubMed ID: 30722037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Under-reporting of gastrointestinal bleeding associated with anticoagulant use using the UK Yellow Card Scheme.
    Shuttleworth P; Baker J; Clark E
    Int J Clin Pharm; 2023 Aug; 45(4):1014-1018. PubMed ID: 37269441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group.
    Bhoombla N; Preston J; Ainsworth J; Bird H; Jadeja M; King C; Hawcutt DB
    Paediatr Drugs; 2020 Jun; 22(3):335-341. PubMed ID: 32253722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
    Klein K; Hazell L; Stolk P; Shakir S
    Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
    Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
    Bracchi RC; Tseliou F; Copeland L; Routledge PA; Thomas A; Woods F; Adams A; Walker J; Jadeja M; Atkinson MD; Ashfield-Watt P
    Br J Clin Pharmacol; 2021 Aug; 87(8):3344-3348. PubMed ID: 33386761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.
    Mokbel K; Daniels R; Weedon MN; Jackson L
    In Vivo; 2022; 36(2):780-800. PubMed ID: 35241534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-medical prescribers and pharmacovigilance: participation, competence and future needs.
    Stewart D; MacLure K; Paudyal V; Hughes C; Courtenay M; McLay J
    Int J Clin Pharm; 2013 Apr; 35(2):268-74. PubMed ID: 23277419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents.
    Davies EC; Green CF; Mottram DR; Pirmohamed M
    Br J Clin Pharmacol; 2010 Jul; 70(1):102-8. PubMed ID: 20642552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing and further developing age-appropriate information for young people about reporting suspected adverse drug reactions.
    Bioletti L; ; Woodward C; Jadeja M; Hawcutt DB
    Br J Clin Pharmacol; 2024 Mar; 90(3):863-870. PubMed ID: 37990602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
    Aagaard L; Hansen EH
    Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.